Others

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022. The data demonstrated that the tetravalent and unique structure of FS118 played a critical role in driving LAG-3 shedding and cell surface reduction by Tumor Infiltrating Lymphocytes (TILs), which enables FS118 to overcome compensatory up regulation of LAG-3 induced by PD-(L) 1 blockade in patients with cancer.  This bi-specific antibody demonstrated simultaneous binding to LAG-3 and PD-L1 with high affinity that resulted in enhancin...